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Abstract
DNA vaccines have many potential benefits but have failed to generate robust immune responses
in humans. Recently, methods such as in vivo electroporation have demonstrated improved
performance, but an optimal strategy for safe, reproducible, and pain-free DNA vaccination
remains elusive. Here we report an approach for rapid implantation of vaccine-loaded polymer
films carrying DNA, immune-stimulatory RNA, and biodegradable polycations into the immune-
cell-rich epidermis, using microneedles coated with releasable polyelectrolyte multilayers. Films
transferred into the skin following brief microneedle application promoted local transfection and
controlled the persistence of DNA and adjuvants in the skin from days to weeks, with kinetics
determined by the film composition. These “multilayer tattoo” DNA vaccines induced immune
responses against a model HIV antigen comparable to electroporation in mice, enhanced memory
T-cell generation, and elicited 140-fold higher gene expression in non-human primate skin than
intradermal DNA injection, indicating the potential of this strategy for enhancing DNA
vaccination.
DNA vaccines have been intensively studied due to potential advantages such as ease of
GMP production, lack of anti-vector immunity, and capability to promote both cellular and
humoral immune responses.1,2 However, plasmid DNA (pDNA) immunization has shown
poor efficacy in non-human primates and human trials,1,3 and the most promising methods
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for increasing the potency of these vaccines have employed involved methods such as in
vivo electroporation that are not attractive for widespread prophylactic vaccination.4 Parallel
to the technical challenges of DNA vaccination, traditional needle-based administration of
vaccines has a number of disadvantages: liquid vaccine formulations typically require
refrigeration that raise the costs and complexity of global distribution (the “cold chain”),5
administration requires trained personnel, and safety is hampered by needle re-use and
needle-based injuries.6 These issues become particularly acute for vaccine distribution in the
developing world.6–8
We hypothesized that DNA vaccine delivery would be substantially enhanced by an
approach that could simultaneously (i) target DNA to tissues rich in immune-response-
governing dendritic cells, (ii) promote sustained transfection without toxicity, (iii) and
provide supporting inflammatory cues to enhance the induction of a potent immune
response. In addition, vaccines have been shown to vary widely in potency depending on the
kinetics of both antigen and adjuvant exposure, with optimal immunity often stimulated by
persistence of antigen and inflammatory signals for up to one week.9–12 To meet these
design goals, we developed a strategy using microneedles to rapidly implant into the skin
biodegradable polymer films, which continuously release DNA polyplexes and adjuvant
molecules in this immunologically-competent tissue over a tunable and sustained period of
time. We show that skin-implanted vaccine multilayers allow control over the physical and
functional persistence of inflammatory adjuvants and pDNA, efficiently transfecting cells in
murine skin and eliciting cellular and humoral immune responses comparable to or
exceeding in vivo electroporation of pDNA, one of the most promising current technologies
for DNA vaccine delivery.4 We have termed this approach of implanting persistent polymer
films into the skin ‘multilayer tattooing’, by analogy to conventional tattooing where
persisting inks are deposited in the skin. These multilayer vaccine formulations allow for
dry-state storage of coated microneedle patches at room temperature for weeks without loss
of activity, an important advantage for decreasing costs and improving vaccine availability
in remote areas. Further, when applied to viable macaque skin ex vivo, multilayer tattooing
elicited 140-fold greater gene expression compared to naked DNA injection. Thus, this
polymer film tattooing approach may offer a route to efficacious DNA vaccines via a pain-
free and self-administrable dry skin-patch platform.
Design, fabrication, and testing of ‘quick-release’ multilayers
We first set out to create implantable vaccine coatings using polyelectrolyte multilayers13,14
(PEMs, Fig. 1a), nanostructured films formed by iterative adsorption of alternately-charged
polymers, which embed large weight-fractions of biologic cargos (e.g., DNA, up to 40% of
total film mass),15 stabilize embedded molecules in the dried state,16,17 and exhibit release
kinetics predetermined by the film architecture/composition. We hypothesized that rapid
multilayer transfer from coated microneedles into the epidermis could be achieved via an
underlying polymer film designed to instantly dissolve when microneedles are applied to the
skin (Fig. 1b), allowing the kinetics of DNA/adjuvant release in the tissue to be tailored
separately from the time required for a microneedle patch to be kept on the skin. To create
such releasable vaccine coatings, we employed a photo-sensitive and pH-responsive
polymer, Poly(o-Nitro-benzyl-methacrylate-co-Methyl-methacrylate-co-Poly(ethylene-
glycol)-methacrylate) (PNMP), for the release-layer. PNMP is initially organic-soluble, but
on brief exposure to UV, cleavage of the o-nitrobenzyl groups converts the polymer to a
weak polyelectrolyte (uv-PNMP) soluble in water above pH ~6.5.18 As shown below, this
photo-switchable solubility provided the means to prove that PEM film implantation
depended on PNMP release-layer dissolution.
DeMuth et al. Page 2
Nat Mater. Author manuscript; available in PMC 2014 March 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Skin patches were fabricated by melt-molding poly(L-lactide) (PLLA) on poly(dimethyl-
siloxane) (PDMS) molds to obtain arrays of microneedles each 250 µm in diameter at their
base and 650 µm in height (Supplementary Fig. S1).19 Biotinylated-PNMP (bPNMP,
Supplementary Fig. S2a) films were coated on microneedles by spray deposition20 from 1,4-
dioxane solutions, UV-exposed to trigger the photochemical transition in the film, and then
stained with fluorescent streptavidin (SAv) to permit visualization of the release-layer by
microscopy. Next, LbL deposition was used to construct an overlying PEM film composed
of Cy5-labeled pDNA encoding luciferase (Cy5-pLUC) and the transfection agent poly-1, a
biodegradable poly(β-amino-ester) (PBAE, Supplementary Fig. S2b).19,21 PEM films were
initiated by depositing 20 bilayers of protamine-sulfate (PS) and poly(4-styrene-sulfonate)
(SPS) to provide a uniform charge density, followed by iterative adsorption of poly-1 and
Cy5-pLUC (Fig. 2a). Profilometry measurements performed on PEMs constructed in
parallel on Si substrates showed linear multilayer growth with increasing deposition cycles
as previously reported for (PBAE/pDNA) films (Fig. 2b).19,21 Confocal imaging of
microneedles coated with composite (uv-bPNMP)(PS/SPS)20(poly-1/Cy5-pLUC)35 PEM
films showed conformal co-localized fluorescence from SAv-labeled uv-bPNMP and Cy5-
pLUC over the surface of each PLLA microneedle (Fig. 2c). (Individual uv-bPNMP and
PEM films were too thin to resolve as distinct layers). When analyzed at sequential stages of
PEM film deposition, the mean total SAv-bPNMP fluorescence signal from single
microneedles was stable but Cy5-pLUC fluorescence linearly increased with increasing
rounds of bilayer deposition, confirming linear film growth on microneedles (Fig. 2d).
Measurement of DNA recovered from microneedle coatings disrupted by treatment with
sodium chloride showed ~4.2µg DNA deposited per bilayer per cm2 of the microneedle
array (Fig. 2d). Sequential assembly of PEM films comprising layers of (poly-1/poly(I:C))
followed by layers of (poly-1/pLUC) generated microneedles coated with complete vaccine
multilayers containing pDNA, a transfection agent, and a strong adjuvant (Fig. 2e). These
composite films showed conformal coating of both vaccine components (Fig. 2f) and linear
growth of pLUC layers over poly(I:C) layers with increasing number of deposition cycles
(Fig. 2g, h). Key to this process is that the DNA-containing PEM is never exposed to UV-
irradiation, thus avoiding any potential damage due to UV exposure.
Lack of toxicity/biocompatibility is critical for materials used in prophylactic vaccines, and
the components of the microneedle system were chosen with biocompatibility in mind:
polylactide used as the microneedle base is a bioresorbable polymer with a long history of
clinical use in resorbable sutures and drug delivery devices. Although we chose to use (PS/
SPS) ‘base-layer’ films for convenience in lab-scale studies, simplified film architectures
composed of only PNMP and (PBAE/nucleic acids) could be deposited with linear growth
per deposition cycle for 20 or more bilayers (data not shown). Previous studies have
demonstrated the biocompatibility of both PNMP in vitro18,22 and poly-1 and poly-2
polymers in vitro and in vivo.23–25 Consistent with these data, we observed no apparent local
toxicity in any of the mice treated throughout these studies.
Multilayer delivery into skin from microneedles
To test PEM film release from microneedle arrays, dried composite (SAv-labeled uv-
bPNMP)(PS/SPS)20(poly-1/Cy5-pLUC)35 coatings (referred to henceforth as PNMP/PEM
films) on microneedles were immersed in pH 7.4 PBS for varying times in vitro and imaged
by confocal microscopy to quantitate uv-bPNMP and Cy5-pLUC fluorescence remaining on
the microneedle surfaces. After 15 minutes incubation in PBS, we observed a significant
loss of both bPNMP and Cy5-pLUC fluorescence from microneedle arrays (Supplementary
Fig. S3). By contrast, no film release was observed if PEMs were assembled onto PNMP
coatings that had not been irradiated to photo-switch the release-layer’s solubility. To
determine whether microneedles coated with releasable films would permit rapid multilayer
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implantation in vivo, we applied dry (PNMP/PEM)-coated microneedles to the auricular skin
of C57Bl/6-MHC II-GFP mice.26 Trypan blue staining of treated skin in this case showed
consistent microneedle insertion (Fig. 3a). Mirroring our in vitro observations, confocal
imaging of microneedles after 15 minutes application to murine skin showed that both uv-
bPNMP and Cy5-pLUC fluorescence was rapidly lost from coated microneedles, but only if
PNMP films were irradiated before multilayer assembly to prime for rapid dissolution of the
release-layer (Fig. 3b, c). Confocal imaging of skin samples following application of
(PNMP/PEM)-coated microneedles for 15 minutes showed significant transfer of Cy5-
pLUC in the epidermis co-localized with MHC II-GFP+ Langerhans cells (LCs) (Fig. 3d)
and up to 400 µm deep into the skin (Fig. 3e), but only when the PNMP layer was UV-
primed. Similarly, microneedles carrying poly(I:C)-loaded PEM films deposited
fluorescently-labeled poly(I:C) into the skin, colocalizing in the same z-plane with MHC II-
GFP-expressing cell populations (Figs. 3f). Twenty-four hours after implantation of (poly-1/
nucleic acid) multilayers, the degrading films were observed dispersed into the tissue around
the needle insertion site and showed apparent uptake in colocalized LCs (Fig. 3g). Thus, the
uv-PNMP release-layer promotes rapid transfer of DNA- or RNA-loaded films from
microneedles into the skin.
Control over nucleic acid persistence and activity in skin via implanted
multilayer composition
We next tested whether the in vivo kinetics of nucleic acid release into the surrounding
tissue could be controlled via the composition of multilayers implanted in the skin. Past
studies have demonstrated the ability of multilayers composed of pDNA assembled with the
PBAEs poly-1 or poly-2 to mediate release with varying kinetics.27,28 Consistent with this
prior work, (PS/SPS)20(poly-1/poly(I:C))35 and (PS/SPS)20(poly-1/pLUC)35 multilayers
constructed on Si substrates exhibited rapid release at 37°C of ~80% pLUC or poly(I:C)
within 24 hours, while analogous films constructed with poly-2 showed a slower release
lasting ~1 week (Supplementary Fig. S4). To determine whether the composition of PBAE
multilayers implanted via microneedle delivery could mediate similar tunable release of
nucleic acid therapeutics in vivo, we constructed (PBAE/Cy5-poly(I:C)) PEM films on uv-
PNMP-coated microneedles using poly-1 or poly-2 as the PBAE component. Following
application of coated microneedles to the skin of C57Bl/6 mice for 15 min, we monitored
the fluorescence signal of implanted Cy5-poly(I:C) over time using whole-animal
fluorescence imaging. Similar to the in vitro trend, films encapsulating poly(I:C) with poly-1
were quickly cleared from the application site, while (poly-2/poly(I:C)) films persisted for
10 days following application (Fig. 4a). To quantify the functional impact of sustained
polyI:C adjuvant release in vivo, we applied microneedles carrying (poly-2/poly(I:C))
multilayers to the auricular skin of mice or injected equivalent doses of free poly(I:C)
intradermally at the same site, and administered the chemiluminescent probe luminol to
trace local inflammation over time. Systemically-injected luminol emits photons when
catabolized by myeloperoxidase (MPO) produced by activated innate immune cells at sites
of inflammation.29,30 As shown in Fig. 4b, bolus poly(I:C) injection elicited a transient burst
of inflammation that resolved by 48 hr, while multilayer implantation resulted in 2-fold
higher peak MPO activity at 24 hr that decayed slowly to baseline over ~1 week.
Importantly, poly(I:C)-triggered inflammation was highly localized to the application site, as
no elevation of systemic cytokines was observed following multilayer implantation (data not
shown). Thus, the composition of implanted PEM films can directly control the kinetics of
release and local inflammatory response in the skin.
The selection of poly-1 and poly-2 as biodegradable polycation components of these PEM
coatings was motivated not only by their ability to regulate nucleic acid release, but also to
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directly promote transfection by forming pDNA polyplexes in situ during film
degradation.21,31 Dynamic light scattering analysis of supernatants collected from these
eroded films in vitro revealed large aggregates (50–300nm, data not shown), consistent with
previous evidence of in situ polyplex formation/release from degrading (PBAE/pDNA)
multilayers.27,31 To determine whether controlled polyplex release from implanted films
would allow gene expression kinetics to be regulated in vivo, we used bioluminescence
imaging to monitor expression of luciferase-encoding DNA longitudinally in live animals.
Although in vivo optical imaging analysis of bioluminescent signals is limited by variable
photon penetration from different tissue depths and locations, it is useful for accurate
comparison of relative signal from identical tissue sites and for longitudinal analysis of the
duration of expression. Microneedles were prepared with (PNMP/PEM) coatings containing
pLUC as before, with or without UV-priming of the PNMP release-layer. We verified that
pDNA released from multilayers in vitro retained bioactivity over the entire course of film
degradation comparable to fresh PBAE/DNA polyplexes (Supplementary Fig. S5). In vivo,
control microneedles (where the release-layer was not UV-primed) applied to the skin of
mice for 15 min led to no detectable expression of pLUC by bioluminescence imaging
(Supplementary Fig. S6), consistent with the lack of detectable film transfer into skin under
this condition. By contrast, mice treated with microneedles coated with (uv-PNMP/PEM)
films showed significant levels of bioluminescence one day after application, demonstrating
transfection of cells in situ (Fig. 4c). Further, the kinetics of pLUC expression varied greatly
depending on the PBAE used: delivery of (poly-1/pLUC) multilayers led to luciferase
expression that peaked after 3 days and declined to background levels after 10 days, while
implantation of slower-degrading (poly-2/pLUC) films showed prolonged bioluminescence,
peaking on day 3 then slowly decreasing to background levels by day 22 (Fig. 4c). Together
this data shows that, multilayer tattooing can be used to tailor the duration of both
inflammatory signals and antigen-encoding DNA expression in vivo, via selection of
constituent polymers with varying degradation rates.
Embedding bioactive molecules in multilayer films has previously been shown to enhance
their stability for dry-state storage at room temperature,16,17 an attractive feature for
vaccines given the costs and availability limitations imposed by the need for refrigeration of
liquid vaccine formulations. To test whether (PBAE/pDNA) multilayer films coated on
microneedles stabilize their DNA cargo for dry storage, we fabricated microneedle arrays
coated with (uv-PNMP/PEM) films and stored them dry at 25°C for 0, 14, or 28 days before
application to the skin of mice as before. Bioluminescence imaging of these animals after
treatment revealed no significant decrease in transfection resulting from storage, indicating
the maintenance of pDNA bioactivity in multilayers for extended durations (Fig. 4d). These
results suggest that microneedles coated with vaccine-containing multilayers could be easily
packaged for inexpensive dry-state storage and transportation to remote areas of the world,
bypassing the ‘cold-chain’ requirements of conventional vaccines.
Enhanced DNA vaccine responses via microneedle-implanted multilayers
Previous work has demonstrated DNA uptake in both keratinocytes and local APCs
following delivery to the skin in both humans and mice, both of which can contribute to
induction of immune responses in DNA vaccination (reviewed in 32). To test the ability of
multilayer tattooing with vaccine-loaded polymer films to enhance DNA immunization, we
coated microneedles with (uv-PNMP)(PS/SPS)20(poly-1/poly(I:C))35(poly-1/pGag)35
composite releasable multilayers containing the adjuvant poly(I:C) and pGag, a plasmid
encoding the model HIV antigen SIV-gag (Fig. 5a). We compared multilayer tattooing to
several control immunizations using the same delivered dose of pGag and poly(I:C):
injection of “naked” pDNA, the most common experimental strategy for DNA
immunization in mice and humans; and in vivo electroporation, where DNA is administered
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in the presence of an electric field to promote DNA uptake.4,33 To confirm the importance
of the pH-responsive release-layer, we also tested microneedles where the PNMP layer was
not UV-treated, and hence unable to dissolve upon skin insertion. Finally, we also compared
immune responses in mice receiving intradermal injections of poly-1/pGag polyplexes, to
determine the importance of the sustained-release multilayer film architecture for generating
immunity. In all cases we immunized groups of animals on days 0 and 28 with 20 µg pGag
and 10 µg poly(I:C). Multilayer tattooing was performed with microneedles (MN ± UV)
applied to the dorsal ear skin for 15 min. Control mice were injected intradermally (ID and
ID Polyplex) in the ear skin, or intramuscularly with or without in vivo electroporation (IM
± EP). Peptide-MHC tetramer staining of peripheral blood mononuclear cells showed that
IM and ID ± Polyplex administration produced only weak antigen-specific CD8+ T cell
responses (Fig. 5b-d). By contrast, microneedle-treated groups showed robust expansion of
Gag-reactive T-cells exceeding 5% of the circulating CD8+ population two weeks following
the boost, a response that was quantitatively similar to frequencies observed for IM + EP
immunized mice (Fig. 5b-d). Notably, the response to MN vaccination was ablated if the
PNMP release-layer was not UV-treated (and was therefore unable to dissolve on
application). Additionally, compared to all of the other vaccination regimens, microneedle
administration generated substantially greater frequencies of CD44+CD62L+ central
memory T-cells, a population thought to be important for recall immunity and long-term
protection (Fig. 5e-f).34 Following injection of naked pDNA 3.5 months after the prime to
test recall responses, large frequencies of IFN-γ-producing CD8+ T-cells were elicited (Fig.
5g), suggesting the establishment of robust T-cell memory. Finally, two weeks following the
boost, we measured total Gag-specific IgG titers in sera and observed a 10-fold increase in
microneedle treated mice over those given any other immunization regimen (P < 0.01, Fig.
5h). Thus, DNA vaccination via multilayer tattooing shows the potential to match (or
exceed) the potency of in vivo electroporation, using a skin patch that can be stored in a dry
state, is painlessly applied with no extraneous apparatus, and could be self-applied in
minutes.
Enhanced transfection of non-human primate skin
While naked DNA injections stimulate immune responses in small animals, responses
observed in non-human primates and humans have been much weaker.1–3 To determine
whether multilayer tattooing could also enhance the efficacy of DNA delivery in non-human
primates, we tested the ability of PNMP-coated microneedles to deliver (poly-1/pLUC)
multilayers into fresh explanted skin from Rhesus macaques ex vivo. Trypan blue staining
and histological sectioning of macaque skin treated with uncoated PLLA microneedles
showed uniform patterns of microneedle insertion into the superficial layers of the skin
without disruption of underlying dermal layers or capillary vessels (Fig. 6a, b). We tested
the ability of microneedles coated with (uv-PNMP/PEM) films to transfect ex vivo cultured
macaque skin explants compared to intradermal injections of equivalent doses of naked
pDNA. Microneedles coated with (PNMP/PEM) multilayers effectively transfected macaque
skin explants following a 15 min application period, but as in mice, transfection only
occurred if the PNMP release-layer was UV-primed for dissolution (Fig. 6c).
Bioluminescence imaging of the treated skin samples showed that microneedle delivery
generated consistent expression of luciferase at 140-fold greater levels compared to
intradermally-injected naked DNA controls for several days (P < 0.01, Fig. 6d). Previous
results in mice have indicated that the magnitude of gene expression following DNA
vaccination correlates with the strength of T-cell responses in vivo.35 Thus, although the
limitations of ex vivo skin explant culture prevent measurement of the long-term duration of
gene expression, these results indicate that microneedle delivery promotes strong initial
DNA expression in non-human primate skin, where naked DNA injection elicits very weak
transfection only a few fold above background. Although the magnitude of gene expression
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is only one parameter determining the ultimate strength of immune responses following
DNA vaccination, the ability to improve expression levels in primates is a significant result
given that poor transfection efficiency is an acknowledged obstacle for improving DNA
immunogenicity in large animal models and humans.33,36
Microneedles have recently shown substantial promise in vaccine delivery,37,38 and several
reports have begun to explore the use of metal microneedles to deliver DNA into the
skin.39–42 These studies have demonstrated the ability of naked DNA delivery by
microneedles to provide enhanced immune responses compared to intramuscular injection,
but only one study compared microneedle administration to alternative approaches designed
to elicit improved transfection; in that test microneedles elicited T-cell responses
comparable to gene gun delivery of DNA if twice the DNA dose was given by the
microneedle array.40 Here we have demonstrated a new approach for DNA vaccination via
multilayer “tattooing”, using microneedles employing a pH-responsive release-layer to
rapidly implant biodegradable vaccine-loaded polymer films into the skin. (Note that this
new approach should not be confused with prior studies of “DNA tattooing”, where DNA
solutions are literally applied to the skin using a commercial tattoo device9,33,43– a
completely different method.) Multilayer tattooing simultaneously addresses several issues
in DNA vaccine delivery: implanted multilayers deliver DNA with transfection agents,
promoting transfection in situ; molecular adjuvants are co-delivered to amplify the immune
response; and we have shown that the multilayer structure allows the kinetics of vaccine
release to be tailored over days to weeks. Combined, these features enabled multilayer
tattooing to elicit immune responses in mice far exceeding naked DNA injections. These
responses were also comparable to in vivo electroporation, an approach currently viewed as
a gold standard for experimental DNA vaccine potency but which requires special
equipment, elicits pain and discomfort in recipients,44,45 and is unlikely to be feasible in
widespread prophylactic vaccination. Notably, vaccines have been shown to vary widely in
potency based on the duration of exposure to antigen and adjuvant combinations.9–12 Our
studies suggest that the continuous release of polyplexes from implanted multilayers may be
critical to the enhanced immunogenicity of multilayer tattooing, as bolus injection of free
polyplexes formed from the same components elicited very weak immune responses.
Finally, we have shown that formulation of DNA vaccines as multilayer coatings on
microneedles provides the opportunity for long term maintenance of DNA bioactivity in a
dried state without refrigeration, addressing cost and availability limitations imposed by the
cold-chain in the global distribution and storage of vaccines. We focused here on DNA
vaccination due to the relevance of needle-free vaccines for global health and the need for
enhanced DNA vaccination strategies. However, the well-known adaptability of multilayers
for incorporation and controlled release of diverse therapeutics15,46–51 suggests this
approach should be applicable to diverse drug delivery applications. Further, the pH-
sensitive release-layer strategy employed here is a generalizable approach to create
selectively-released multilayer films. While the true potential of any vaccination strategy
can only be established in human clinical trials, the data shown here suggest that multilayer
tattooing is a promising approach to enhance the efficacy of DNA vaccines, a platform
technology with the potential to be applied universally in vaccine development.
Materials and Methods
Materials
(b)PNMP (31:59:10 oNBMA:MMA:PEGMA by mol, 17 kDa), poly-1 (15 kDa), and poly-2
(20 kDa) were synthesized as previously reported.18,24 AL-11/H-2Kb-peptide-MHC II
tetramers were provided by the NIH tetramer core facility.
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PLLA microneedle fabrication
PDMS molds (Sylgard 184, Dow-Corning, Midland, Michigan) were prepared using a
Clark-MXR-CPA-2010 (VaxDesign Inc., Orlando, Florida). PLLA (IV 1.9 dL/g, Lakeshore
Biomaterials) was melted over the molds under vacuum (−25 in. Hg, 200°C, 40 min), and
then cooled to −20°C before removal and crystallization at 140°C for 4 hr for solvent
resistance.
PNMP release-layer deposition
On Si substrates, 3 wt% PNMP in 1,4-dioxane was deposited using a Specialty Coating
Systems P6700 (Indianapolis, Indiana). On PLLA microneedles, 0.25 wt% (b)PNMP was
spray deposited as previously described (0.2mL/s, 15 cm range, 10s).20 Films were dried
under vacuum at 25°C for 12 hr. bPNMP release-layers were labeled with Alexafluor-488-
conjugated-SAv (10 µg/mL in PBS pH 6.0, Sigma-Aldrich, St. Louis, Missouri).
Polymer multilayer film preparation
LbL films were assembled using a Carl Ziess HMS-DS50 stainer. Films were constructed on
Si wafers and PLLA microneedles following deposition of (b)PNMP and photoswitching via
UV-irradiation (254 nm, 2.25 mW/cm2) for 15 min. (PS/SPS) base layers were deposited
through alternative immersion into PS (2 mg/mL, Sigma-Aldrich) and SPS (5 mM, Sigma-
Aldrich) for 10 min, separated by two 1 min PBS rinses. (PBAE/nucleic acid) multilayers
were deposited similarly, alternating 5 min dips in poly-1/2 (2 mg/mL) and either pLUC,
pGag, or poly(I:C) (Invivogen, San Diego, California) solutions (1 mg/ml) separated by two
30 sec PBS rinses. Fluorescent pLUC and poly(I:C) were prepared using Cy5 and
tetramethyl-rhodamine (TMR) Label-IT reagent (Mirus Bio Corporation, Madison,
Wisconsin). All solutions were in PBS, adjusted to pH 5.0. Films were characterized using a
Veeco Dektak profilometer and a Zeiss LSM510. Data analysis was performed using Image
J. Film loading was determined using a SpectraMax 250 following elution of films in PBS,
pH 7.4, 2M NaCl for 24 hours.
In Vitro/In Vivo Delivery
For in vitro release experiments, (PS/SPS)20(PBAE/nucleic acid)35 films were incubated in
PBS at 37°C and aliquots were assayed for pLUC or poly(I:C) using picogreen or ribogreen
assay kits (Invitrogen). For in vitro delivery, coated microneedles were incubated in PBS,
pH 7.4 and imaged by confocal microscopy. In vivo delivery experiments were performed
on anesthetized C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine) and MHC II-GFP
transgenic mice (a gift from Prof. Hidde Ploegh).26 Ears were rinsed with PBS on the dorsal
side and dried before application of microneedle arrays by gentle pressure. Applied
microneedles were imaged by confocal. Treated skin was excised and stained with trypan
blue for needle penetration. Ears treated with Cy5-pLUC- or TMR-poly(I:C)-coated
microneedles (±UV-treatment) were mounted and imaged by confocal. Clearance of
fluorescent poly(I:C) and transfection in mice treated with pLUC-coated arrays (±UV-
treatment) was measured using an IVIS Spectrum 200 (Caliper Lifesciences, Hopkinton,
Massachusetts). For luminescent measurements of pLUC expression, mice were imaged
following IP administration of D-luciferin (150mg/kg). For luminescent imaging of MPO-
dependent oxidative burst, luminol sodium salt (Santa Cruz Biotech, Santa Cruz, California)
was administered IP (250mg/kg) before imaging as previously described.29 Fluorescence/
bioluminescence data was processed using region of interest (ROI) analysis with
background subtraction and internal control ROI comparison to untreated skin using the
Living Image 4.0 software package (Caliper).
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Vaccinations
Animal studies were approved by the MIT IUCAC and animals were cared for in the
USDA-inspected MIT Animal Facility under federal, state, local, and NIH guidelines for
animal care. Groups of 4 C57Bl/6 mice were immunized with 20 µg pGag and 10 µg
poly(I:C) by intramuscular injection (15µl, quadriceps) with or without in vivo
electroporation (Harvard Apparatus ECM830, 2x60ms pulses, 200V/cm), intradermal
injection (15µl, dorsal ear skin, poly(I:C) mixed with free DNA or DNA/poly-1 polyplexes),
or by microneedle array (15 min application of (PS/SPS)20(poly-1/poly(I:C))35(poly-1/
pGag)35 on uv-PNMP and native-PNMP coated PLLA arrays). To form poly-1/pDNA
polyplexes, pDNA was mixed as previously described with PBAE (1:1 ratio by mass) in
deionized water and vortexed briefly prior to injection.52 All animals received the same
delivered doses of pGag and poly(I:C); microneedle-delivered dosages were determined by
comparison of total eluted pDNA from coated arrays before and after treatment. Frequencies
of Gag-specific CD8+ T-cells and their phenotypes were determined by flow cytometry
analysis of peripheral blood mononuclear cells following staining with DAPI (live/dead),
anti-CD8α, anti-CD44, anti-CD62L, and AL-11/H-2Kb-peptide-MHC tetramers. Anti-Gag
IgG titers, defined as the dilution of sera at which OD reading was 0.25, were determined by
ELISA using SIV-mac251 (My Biosource, San Diego, California) coated plates, and UV-
Vis detection of peroxidase conversion of tetramethybenzydine (KPL, Gaithersburg,
Maryland) using HRP-conjugated anti-IgG (Jackson Immunoresearch, West Grove,
Pennsylvania). To assess recall responses, microneedle-treated animals were challenged
with 50 µg intramuscular pGag in the quadriceps and cytokine expression was measured by
flow cytometry in peripheral blood mononuclear cells following stimulation with AL11
peptide, treatment with brefeldin A, and staining with DAPI, anti-CD8α, and anti-IFNγ,
anti-TNFα.
Ex vivo Macaque Skin Culture and Microneedle Testing
Macaque studies were approved by the Harvard Medical School IACUC. Outbred Rhesus
monkeys were housed at New England Primate Research Center. Fresh skin was obtained
from the quadriceps of euthanized Rhesus macaques. Skin was mounted on slides and
microneedles were applied by gentle pressure. Skin was stained using trypan blue for needle
insertion, formaldehyde fixed, and embedded in parrafin for histological sectioning,
hemotoxylin and eosin staining, and optical imaging. To assay ex vivo transfection, pLUC
was injected intradermally (20µg in 10µl PBS) or delivered by microneedle in (PS/
SPS)20(poly-1/pLUC)35 multilayers overlying native or uv-PNMP. Skin was cultured as
previously described53 and imaged using an IVIS Spectrum after addition of 300 μg
luciferin to the culture media. Data analysis was performed as before using the Living Image
Software package.
Statistical Analysis
Statistical analysis was performed with Graphpad Prism (La Jolla, California) using two-
way analysis of variance or t-test. Values are reported as mean ± s.e.m.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Design of quick-release vaccine-loaded microneedle coatings
a, Schematic view of release-layer-mediated multilayer tattooing strategy using coated
microneedles: (1) PLLA microneedles are coated with PNMP release-layer films through
spray deposition; (2) UV-irradiation imparts pH-sensitive aqueous solubility to the PNMP
film, forming a uv-PNMP ‘release-layer’; (3) Overlying multilayer films containing nucleic
acids are constructed using LbL deposition at pH 5.0. b, Mechanism of action for multilayer
tattooing: (1) Microneedle application to skin and exposure to interstitial fluid gives rapid
release-layer dissolution, mediating overlying film delamination and retention in skin
following microneedle removal; (2) Implanted films provide sustained release of nucleic
acids through hydrolytic PBAE degradation and release of in situ-formed PBAE/nucleic acid
polyplexes; (3) released polyplexes mediate local transfection and immune modulation in
the tissue.
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Figure 2. LbL assembly of microneedle coatings carrying DNA, immunostimulatory RNA, and
transfection agents
a, Film architecture for (uv-PNMP)(PS/SPS)n(PBAE/pLUC)n multilayers. b, Growth of
(poly-1/pLUC)n and (poly-2/pLUC)n multilayers assembled onto (uv-PNMP)(PS/SPS)20
films on silicon substrates as a function of the number of deposited (PBAE/pLUC) bilayers
as measured by surface profilometry. c, Representative confocal images of PLLA
microneedles coated with (SAv488-bPNMP)(PS/SPS)20(poly-1/Cy5-pLUC)35 films (left –
transverse optical sections, right – lateral sections, 100µm z-intervals, scale bars 200 µm.
(blue – Sav488-uv-bPNMP, yellow – Cy5-pLUC). d, Quantification of Cy5-pLUC and
Sav488-bPNMP incorporated into (SAv488-bPNMP)(PS/SPS)20(poly-1/Cy5-pLUC)n films
on microneedles through confocal fluorescence intensity analysis (left axis, n = 15) and
measurement of total DNA recovered from dissolved films (right axis, n = 3). e, Film
architecture for (uv-PNMP)(PS/SPS)20(Poly-1/pLUC)n(Poly-1/poly(I:C))n multilayers. f,
Representative confocal images of microneedles coated with (SAv488-uv-bPNMP)(PS/
SPS)20(poly-1/TMR-poly(I:C))15(poly-1/Cy5-pLUC)15 films (left – transverse sections,
right – lateral sections, 100µm z-interval, scale 200 µm. (blue – Sav488-uv-bPNMP, yellow
– Cy5-pLUC, red – TMR-poly(I:C)). g, h, Quantification of Cy5-pLUC, TMR-poly(I:C),
and SAv488-bPNMP incorporated into (SAv488-bPNMP)(PS/SPS)20(poly-1/TMR-
poly(I:C))n(poly-1/Cy5-pLUC)n films on microneedles through confocal fluorescence
intensity analysis (g, n = 15) and measurement of total nucleic acids recovered from
dissolved films (h, n= 3).
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Figure 3. PNMP release-layers promote rapid implantation of multilayer films at microneedle
penetration sites in vivo
a, Optical micrograph of ear skin stained with trypan blue to reveal epidermal penetration
following PLLA microneedle application (scale bar 500µm). b, Representative confocal
images of (SAv488-bPNMP)(PS/SPS)20(poly-1/Cy5-pLUC)35-coated PLLA microneedles
with or without UV sensitization of the PNMP layer (Blue - Sav488-bPNMP; yellow - Cy5-
pLUC), before application, or after 15 min application to murine ear skin (lateral sections,
100 µm z-interval, scale bar 200 µm). c, Quantitation of confocal fluorescence intensities (n
= 15) showing loss of Sav488-uv-bPNMP and Cy5-pLUC films from coated microneedles
upon application to skin, dependent on UV-induced photo-switching of the PNMP layer
DeMuth et al. Page 15
Nat Mater. Author manuscript; available in PMC 2014 March 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
solubility. ***, p< 0.0001, analyzed by unpaired t-test. d, Representative confocal image of
treated murine skin showing film implantation after 15 min (green, MHC II-GFP; yellow,
Cy5-pLUC; penetration site outlined, scale bar 100µm). e, x-y/x-z/y-z confocal images
showing depth of Cy5-pLUC film deposition after 15 minute microneedle application
(green, MHC II-GFP; yellow, Cy5-pLUC; penetration sites outlined, scale bar 200µm). f,
Representative confocal image of treated murine skin showing TMR-poly(I:C) film
implantation after 15 min microneedle application (green, MHC II-GFP; red, TMR-
poly(I:C); penetration site outlined, scale bar 100 µm). g, Colocalization and uptake of
TMR-poly(I:C) by MHC II-GFP+ LCs at microneedle insertion site 24 hrs following film
implantation (green, MHC II-GFP; red, TMR-poly(I:C); yellow, overlay, scale bar 50 µm).
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Figure 4. Implanted films control the physical and functional persistence of pDNA and poly(I:C)
in vivo
a, Representative whole-animal fluorescence images showing TMR-poly(I:C) retention at
the application site and quantitative analysis of normalized total fluorescence R(t) relative to
initial fluorescence Ro from groups of animals (n = 3) over time following 15 min
application of PLLA microneedles coated with (uv-PNMP)(PS/SPS)20(PBAE/TMR-
poly(I:C))35 multilayers containing poly-1 or poly-2 as the PBAE component. b,
Representative whole-animal luminescent images and quantitative analysis of luminol signal
from MPO-dependent oxidative burst in activated phagocytes at the treatment site over time
following intradermal injection of 10 µg poly(I:C) or 15 min application of PLLA
microneedles coated with (uv-PNMP)(PS/SPS)20(Poly-2/poly(I:C))35 multilayers. c,
Representative whole animal bioluminescence images of pLUC expression at the application
site and mean bioluminescence intensity over time following 15 minute application of
microneedles coated with (uv-PNMP)(PS/SPS)20(PBAE/pLUC)35 multilayers containing
poly-1 or poly-2 as the PBAE component. d, Mean bioluminescent intensity on day 2
following 15 min application of microneedles coated with (uv-PNMP)(PS/SPS)20(Poly-1/
pLUC)35 multilayers stored dry at 25°C for 0, 14, or 28 days.
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Figure 5. Microneedle tattooing with multilayer films carrying pDNA and poly(I:C) generates
potent cellular and humoral immunity against a model HIV antigen
a, C57Bl/6 mice (n = 4 mice/group) were immunized with 20 µg pGag and 10 µg poly(I:C)
on days 0 and 28 intramuscularly (with or without electroporation (EP)) in the quadriceps,
intradermally in the dorsal ear skin (with free pGag or pGag/poly-1 polyplexes, ID ±
Polyplex), or by 15 minute application of (PNMP)(PS/SPS)20(poly-1/poly(I:C))35(poly-1/
pLUC)35–coated microneedles without or without UV priming of the PNMP release-layer
(MN ± UV) to the dorsal ear skin. b-d, Frequency of Gag-specific CD8+ T-cells in
peripheral blood assessed by flow cytometry analysis of tetramer+ CD8+ T-cells. Shown are
mean tetramer+ values from b, day 14 and c, representative cytometry plots from individual
mice and d, mean tetramer+ values from day 42. e-f, Analysis of T-cell effector/central
memory phenotypes in peripheral blood by CD44/CD62L expression of tetramer+ cells from
peripheral blood. Shown are e, representative cytometry plots from individual mice at day
49 and f, mean percentages of tetramer+CD44+CD62L+ among CD8+ T cells at day 98. g,
Mice immunized with microneedles were recalled on day 105 by IM injection of 50 µg
pGag, and assessed for cytokine production on ex vivo restimulation with AL11 peptide on
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day 112. Shown is representative flow cytometry analysis of IFN-γ/TNF-α-producing CD8+
T-cells. h, Enzyme-linked-immunosorbent assay analysis of total Gag-specific IgG in sera at
day 42. **, p< 0.005, analyzed by two-way ANOVA.
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Figure 6. Multilayer tattooing enhances transfection in non-human primate skin
a, Optical micrograph of macaque quadriceps skin showing microneedle penetration pattern
stained using trypan blue (scale bar 500µm). b, Histological section of microneedle-treated
macaque skin showing epidermal disruption at microneedle insertion sites (boxed, left, scale
bar 500µm; right, scale bar 100µm). c, Bioluminescence images of luciferase expression 2
days following pLUC delivery by ID injection or microneedle tattooing with (PS/
SPS)20(poly-1/pLUC)35 films from either uv-PNMP- or non-irradiated PNMP-coated
microneedles following a 15 minute application. d, Quantification of total bioluminescent
signal in cultured skin tissue explants 1, 2, and 3 days following treatment. ***, p< 0.0001,
analyzed by unpaired t-test.
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